Research programme: nanolipogel based oncology therapeutics - Saugatuck Therapeutics
Alternative Names: NLG-PD1 formulations; PORT-4 based oncology therapeuticsLatest Information Update: 28 Apr 2024
At a glance
- Originator Saugatuck Therapeutics
- Class Antineoplastics; Drug conjugates; Nucleotide aptamers
- Mechanism of Action Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 31 May 2021 Saugatuck Therapeutics has patent protection for more than 60 patents for different technologies, including intratumoral delivery, iNKT agonists, nanolipogel and DNA aptamers and VLP delivery platform
- 31 May 2021 Saugatuck Therapeutics has patents pending for different technologies, including intratumoral delivery, iNKT agonists, nanolipogel and DNA aptamers and VLP delivery platform worldwide